Caxton Associates LLP Acquires Shares of 33,664 ADMA Biologics Inc $ADMA

Key Points

• Caxton Associates LLP invested approximately $668,000 in ADMA Biologics, acquiring 33,664 shares during the first quarter of the year.
• Insider trading was noted as Director Steve Elms sold 194,749 shares of ADMA Biologics, resulting in a significant 69.04% decrease in his ownership of the stock.
• ADMA Biologics reported a quarterly revenue of $121.98 million, a 13.8% increase year-on-year, alongside earnings per share of $0.15, which slightly surpassed analysts' expectations.

Caxton Associates LLP acquired a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 33,664 shares of the biotechnology company's stock, valued at approximately $668,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Cetera Investment Advisers grew its stake in shares of ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after buying an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after purchasing an additional 711 shares during the last quarter. GF Fund Management CO. LTD. grew its stake in shares of ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 1,089 shares during the last quarter. Journey Strategic Wealth LLC grew its stake in shares of ADMA Biologics by 6.6% in the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after purchasing an additional 1,102 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of ADMA Biologics by 11.5% in the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock worth $223,000 after purchasing an additional 1,154 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Up 0.8%

Shares of NASDAQ ADMA traded up $0.13 during trading hours on Wednesday, hitting $15.82. The company's stock had a trading volume of 371,240 shares, compared to its average volume of 3,122,424. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of 18.43 and a beta of 0.54. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The business has a 50-day simple moving average of $17.38 and a 200-day simple moving average of $18.96.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. During the same period last year, the firm earned $0.13 earnings per share. On average, analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.